Clinical Trial Update: Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab and rucaparib in recurrent cervical or endometrial cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Rucaparib (rucaparib)

Snippet

Sponsor: University of Oklahoma | Conditions: Cervical Cancer, Endometrial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-05-28